300871 回盛生物
已收盘 03-05 15:00:00
资讯
新帖
简况
回盛生物：公司在研发项目过程中也在运用AI技术以提高研发效率
证券之星 · 02-26
回盛生物：公司在研发项目过程中也在运用AI技术以提高研发效率
回盛生物：已预约2026年4月17日披露《2025年年度报告》
证券日报 · 02-26
回盛生物：已预约2026年4月17日披露《2025年年度报告》
回盛生物（300871）披露2026年第一次临时股东会决议公告，2月25日股价上涨0.44%
证券之星 · 02-25
回盛生物（300871）披露2026年第一次临时股东会决议公告，2月25日股价上涨0.44%
回盛生物（300871）披露2023年员工持股计划第二批股份锁定期届满提示性公告，2月5日股价下跌1.34%
证券之星 · 02-05
回盛生物（300871）披露2023年员工持股计划第二批股份锁定期届满提示性公告，2月5日股价下跌1.34%
回盛生物(300871.SZ)拟推2026年员工持股计划
智通财经 · 02-05
回盛生物(300871.SZ)拟推2026年员工持股计划
回盛生物最新公告：投资10亿元建设新疆合成生物学智造项目
证券之星 · 02-05
回盛生物最新公告：投资10亿元建设新疆合成生物学智造项目
最高4379%！6家A股公司净利同比预增超10倍
21世纪经济报道 · 01-28
最高4379%！6家A股公司净利同比预增超10倍
回盛生物（300871）披露控股股东部分股份质押公告，1月27日股价下跌8.37%
证券之星 · 01-27
回盛生物（300871）披露控股股东部分股份质押公告，1月27日股价下跌8.37%
1月26日回盛生物（300871）龙虎榜数据：机构净买入1.17亿元
证券之星 · 01-26
1月26日回盛生物（300871）龙虎榜数据：机构净买入1.17亿元
异动快报：回盛生物（300871）1月26日10点16分触及涨停板
证券之星 · 01-26
异动快报：回盛生物（300871）1月26日10点16分触及涨停板
回盛生物（300871）披露关于控股股东部分股份质押的公告，1月14日股价上涨1.84%
证券之星 · 01-14
回盛生物（300871）披露关于控股股东部分股份质押的公告，1月14日股价上涨1.84%
回盛生物（300871）股东武汉统盛投资有限公司质押110万股，占总股本0.54%
证券之星 · 01-14
回盛生物（300871）股东武汉统盛投资有限公司质押110万股，占总股本0.54%
股市必读：回盛生物（300871）预计2025年全年归属净利润盈利2.35亿元至2.71亿元
证券之星 · 01-12
股市必读：回盛生物（300871）预计2025年全年归属净利润盈利2.35亿元至2.71亿元
回盛生物（300871）披露2025年度业绩预告，1月9日股价上涨0.76%
中金财经 · 01-10
回盛生物（300871）披露2025年度业绩预告，1月9日股价上涨0.76%
回盛生物(300871.SZ)发预盈，预计2025年度归母净利润2.35亿元至2.71亿元
智通财经网 · 01-09
回盛生物(300871.SZ)发预盈，预计2025年度归母净利润2.35亿元至2.71亿元
回盛生物：公司定增项目处于审核阶段
证券之星 · 01-07
回盛生物：公司定增项目处于审核阶段
股市必读：回盛生物（300871）12月23日董秘有最新回复
证券之星 · 2025-12-24
股市必读：回盛生物（300871）12月23日董秘有最新回复
回盛生物（300871）披露使用部分闲置募集资金进行现金管理，12月23日股价下跌0.81%
证券之星 · 2025-12-23
回盛生物（300871）披露使用部分闲置募集资金进行现金管理，12月23日股价下跌0.81%
回盛生物：原料药产能利用率较高
证券之星 · 2025-12-23
回盛生物：原料药产能利用率较高
回盛生物：二级市场股价受多种因素综合影响
证券之星 · 2025-11-24
回盛生物：二级市场股价受多种因素综合影响
加载更多
公司概况
公司名称：
武汉回盛生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2020-08-24
主营业务：
武汉回盛生物科技股份有限公司的主营业务是兽用药品(包括化药制剂、原料药、中药制剂)、饲料及添加剂的研发、生产和销售。公司的主要产品是原料药、化药制剂、中药制剂、饲料及添加剂。
发行价格：
33.61
{"stockData":{"symbol":"300871","market":"SZ","secType":"STK","nameCN":"回盛生物","latestPrice":25.5,"timestamp":1772694216000,"preClose":25.39,"halted":0,"volume":5810593,"delay":0,"changeRate":0.0043,"floatShares":202000000,"shares":202000000,"eps":1.0647,"marketStatus":"已收盘","change":0.11,"latestTime":"03-05 15:00:00","open":25.87,"high":25.97,"low":25.27,"amount":148000000,"amplitude":0.0276,"askPrice":25.5,"askSize":516,"bidPrice":25.49,"bidSize":5,"shortable":0,"etf":0,"ttmEps":1.0647,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772760600000},"marketStatusCode":5,"adr":0,"adjPreClose":25.39,"symbolType":"stock","openAndCloseTimeList":[[1772674200000,1772681400000],[1772686800000,1772694000000]],"highLimit":27.93,"lowLimit":22.85,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":202332557,"isCdr":false,"pbRate":2.44,"roa":"--","peRate":23.950409,"roe":"10.35%","epsLYR":-0.1215,"committee":-0.668593,"marketValue":5159000000,"turnoverRate":0.0287,"status":0,"floatMarketCap":5159000000},"requestUrl":"/m/hq/s/300871","defaultTab":"news","newsList":[{"id":"2614304129","title":"回盛生物：公司在研发项目过程中也在运用AI技术以提高研发效率","url":"https://stock-news.laohu8.com/highlight/detail?id=2614304129","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614304129?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:53","pubTimestamp":1772110380,"startTime":"0","endTime":"0","summary":"公司密切关注AI技术在兽药行业的发展与应用，将AI等先进数字技术融入公司研发、生产、经营管理等方面。目前，公司在研发项目过程中，也在运用AI技术以提高研发效率，但相关研究短期内不会对公司经营业绩产生直接影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600035446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300871"],"gpt_icon":0},{"id":"2614351045","title":"回盛生物：已预约2026年4月17日披露《2025年年度报告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2614351045","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614351045?lang=zh_cn&edition=full","pubTime":"2026-02-26 19:10","pubTimestamp":1772104200,"startTime":"0","endTime":"0","summary":"登录新浪财经APP 搜索【信披】查看更多考评等级\n 证券日报网讯 2月26日，回盛生物在互动平台回答投资者提问时表示，公司严格按照定期报告披露格式指引的要求，编制和披露定期报告，确保信息披露的真实、准确、完整。公司已预约2026年4月17日披露《2025年年度报告》。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-26/doc-inhpcyyh4332516.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-26/doc-inhpcyyh4332516.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","300871"],"gpt_icon":0},{"id":"2614331430","title":"回盛生物（300871）披露2026年第一次临时股东会决议公告，2月25日股价上涨0.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614331430","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614331430?lang=zh_cn&edition=full","pubTime":"2026-02-25 22:25","pubTimestamp":1772029521,"startTime":"0","endTime":"0","summary":"截至2026年2月25日收盘，回盛生物报收于27.37元，较前一交易日上涨0.44%，最新总市值为55.38亿元。公司于2026年2月25日发布《2026年第一次临时股东会决议公告》。关联股东对关联交易议案回避表决。会议召集召开程序合法，决议有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500038133.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300871","BK0239"],"gpt_icon":0},{"id":"2609309810","title":"回盛生物（300871）披露2023年员工持股计划第二批股份锁定期届满提示性公告，2月5日股价下跌1.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609309810","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609309810?lang=zh_cn&edition=full","pubTime":"2026-02-05 22:10","pubTimestamp":1770300631,"startTime":"0","endTime":"0","summary":"公司于近日披露《关于2023年员工持股计划第二批股份锁定期届满的提示性公告》。公告显示，武汉回盛生物科技股份有限公司2023年员工持股计划第二批股份锁定期于2026年2月5日届满，解锁日为2026年2月6日，可解锁比例为30%，对应股票数量490,635股，占公司当前总股本的0.24%。公司员工持股计划存续期为48个月，自2024年2月6日起计算，分三期解锁，每期分别解锁40%、30%、30%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500039387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300871","BK0239"],"gpt_icon":0},{"id":"2609372298","title":"回盛生物(300871.SZ)拟推2026年员工持股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2609372298","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609372298?lang=zh_cn&edition=full","pubTime":"2026-02-05 20:18","pubTimestamp":1770293902,"startTime":"0","endTime":"0","summary":"智通财经APP讯，回盛生物(300871.SZ)披露2026年员工持股计划(草案)，参与对象总人数不超过14人，拟筹集资金总额不超过人民币308.10万元，以“份”作为认购单位，每份份额为1.00元，员工持股计划的份数上限为308.10万份。员工持股计划股票来源为公司回购专用证券账户回购的回盛生物A股普通股股票。本计划经公司股东会审议通过后，将通过非交易过户等法律法规允许的方式受让公司回购专用证券账户所持有的公司股份。员工持股计划受让的股份总数不超过20.54万股，占员工持股计划草案公告日公司股本总额的0.10%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402229.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300871"],"gpt_icon":0},{"id":"2609644372","title":"回盛生物最新公告：投资10亿元建设新疆合成生物学智造项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2609644372","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609644372?lang=zh_cn&edition=full","pubTime":"2026-02-05 20:00","pubTimestamp":1770292845,"startTime":"0","endTime":"0","summary":"回盛生物(300871.SZ)公告称，公司于2月4日召开董事会，审议通过全资子公司新疆回盛投资建设新疆合成生物学智造项目，项目总投资10亿元，分三期建设。项目旨在满足市场需求，突破产能与效率瓶颈，实现技术升级和成本控制目标。项目符合西部地区鼓励类产业政策，可享受当地税收优惠，并满足绿色发展要求。项目存在市场、技术和国际贸易风险，公司将通过加强市场监测、加大研发投入和拓展海外渠道来应对。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500035808.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300871","BK0239"],"gpt_icon":0},{"id":"2606982777","title":"最高4379%！6家A股公司净利同比预增超10倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2606982777","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606982777?lang=zh_cn&edition=full","pubTime":"2026-01-28 15:29","pubTimestamp":1769585351,"startTime":"0","endTime":"0","summary":"作为业绩预增榜首，宁波富邦在1月27日晚披露的业绩预告中表示，预计2025年度实现归属于母公司所有者的净利润为5000万元到7000万元，与上年同期相比，将增加4843.73万元到6843.73万元，同比将增长3099.59%到4379.43%。整体看，A股已发布业绩预告的公司中，2025年度净利同比预增超100%有253家，其中有123家扭亏、130家预增。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128153218a6b63e20&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128153218a6b63e20&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["002553","BK1592","SG9999003461.SGD","300850","BK1594","BK1190","600768","600867","601388","01772","300871","SG9999006597.SGD","BK1509","BK1129"],"gpt_icon":0},{"id":"2606780363","title":"回盛生物（300871）披露控股股东部分股份质押公告，1月27日股价下跌8.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606780363","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606780363?lang=zh_cn&edition=full","pubTime":"2026-01-27 22:05","pubTimestamp":1769522716,"startTime":"0","endTime":"0","summary":"武汉回盛生物科技股份有限公司于近日收到控股股东武汉统盛投资有限公司通知，其持有的1,100,000股公司股份被质押，占其所持股份比例1.33%，占公司总股本0.54%，质押用途为银行融资担保，质权人为湖北银行股份有限公司武汉武昌支行。本次质押后，武汉统盛投资有限公司累计质押股份4,200,000股，占其所持股份比例5.07%，占公司总股本2.08%。已质押股份及未质押股份均无冻结、限售情况。公司表示控股股东质押股份暂无平仓风险，不会影响公司控制权稳定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700041552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300871"],"gpt_icon":0},{"id":"2606191322","title":"1月26日回盛生物（300871）龙虎榜数据：机构净买入1.17亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606191322","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606191322?lang=zh_cn&edition=full","pubTime":"2026-01-26 18:27","pubTimestamp":1769423231,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年1月26日公布的交易公开信息显示，回盛生物因日涨幅达到15%的前5只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年1月26日收盘，回盛生物报收于32.62元，上涨20.01%，涨停，换手率18.97%，成交量38.37万手，成交额11.83亿元。从龙虎榜公布的当日买卖数据来看，机构合计净买入1.17亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600025323.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300871"],"gpt_icon":0},{"id":"2606267046","title":"异动快报：回盛生物（300871）1月26日10点16分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2606267046","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606267046?lang=zh_cn&edition=full","pubTime":"2026-01-26 10:20","pubTimestamp":1769394039,"startTime":"0","endTime":"0","summary":"证券之星1月26日盘中消息，10点16分回盛生物触及涨停板。其所属行业动物保健目前上涨。该股为动物保健，宠物经济，合成生物概念热股，当日动物保健概念上涨2.27%，宠物经济概念上涨0.74%，合成生物概念上涨0.06%。1月23日的资金流向数据方面，主力资金净流出3549.17万元，占总成交额6.28%，游资资金净流入264.88万元，占总成交额0.47%，散户资金净流入3284.28万元，占总成交额5.81%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600006460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300871","BK0239"],"gpt_icon":0},{"id":"2603614221","title":"回盛生物（300871）披露关于控股股东部分股份质押的公告，1月14日股价上涨1.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603614221","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603614221?lang=zh_cn&edition=full","pubTime":"2026-01-14 22:20","pubTimestamp":1768400427,"startTime":"0","endTime":"0","summary":"公司近日发布公告称，武汉回盛生物科技股份有限公司于近日收到控股股东武汉统盛投资有限公司通知，其持有的1,100,000股公司股份被质押，占其所持股份比例1.33%，占公司总股本0.54%，质押用途为银行融资担保，质权人为湖北银行股份有限公司武汉武昌支行。本次质押后，武汉统盛投资有限公司累计质押股份3,100,000股，占其所持股份3.74%。公司控股股东质押股份无平仓风险，不会影响公司控制权稳定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400041275.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300871","BK0239"],"gpt_icon":0},{"id":"2603969216","title":"回盛生物（300871）股东武汉统盛投资有限公司质押110万股，占总股本0.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603969216","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603969216?lang=zh_cn&edition=full","pubTime":"2026-01-14 18:30","pubTimestamp":1768386651,"startTime":"0","endTime":"0","summary":"证券之星消息，回盛生物1月14日公开信息显示，股东武汉统盛投资有限公司向湖北银行股份有限公司武汉武昌支行合计质押110.0万股，占总股本0.54%。质押详情见下表：截止本公告日，股东武汉统盛投资有限公司已累计质押股份310.0万股，占其持股总数的3.74%。回盛生物主营业务：兽用药品、饲料及添加剂的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400033981.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300871"],"gpt_icon":0},{"id":"2602271552","title":"股市必读：回盛生物（300871）预计2025年全年归属净利润盈利2.35亿元至2.71亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602271552","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602271552?lang=zh_cn&edition=full","pubTime":"2026-01-12 01:47","pubTimestamp":1768153633,"startTime":"0","endTime":"0","summary":"交易信息汇总资金流向1月9日主力资金净流出1269.93万元；游资资金净流出1557.79万元；散户资金净流入2827.72万元。业绩披露要点业绩预告回盛生物发布业绩预告，预计2025年全年归属净利润盈利2.35亿元至2.71亿元。公司公告汇总武汉回盛生物科技股份有限公司2025年度业绩预告武汉回盛生物科技股份有限公司预计2025年度归属于上市公司股东的净利润为23,500万元至27,100万元，较上年同期扭亏为盈，同比增长1,265.93%至1,444.54%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200000765.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300871"],"gpt_icon":0},{"id":"2602230021","title":"回盛生物（300871）披露2025年度业绩预告，1月9日股价上涨0.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602230021","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602230021?lang=zh_cn&edition=full","pubTime":"2026-01-10 08:56","pubTimestamp":1768006561,"startTime":"0","endTime":"0","summary":"公司近日发布《武汉回盛生物科技股份有限公司2025年度业绩预告》，预计2025年度归属于上市公司股东的净利润为23,500万元至27,100万元，较上年同期扭亏为盈，同比增长1,265.93%至1,444.54%。扣除非经常性损益后的净利润预计为21,250万元至24,850万元，同比增长1,408.61%至1,630.30%。此外，可转换公司债券提前赎回导致财务费用减少，非经常性损益对净利润影响约为2,250万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260110/31931455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300871","BK0239"],"gpt_icon":0},{"id":"2602236073","title":"回盛生物(300871.SZ)发预盈，预计2025年度归母净利润2.35亿元至2.71亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602236073","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602236073?lang=zh_cn&edition=full","pubTime":"2026-01-09 16:13","pubTimestamp":1767946396,"startTime":"0","endTime":"0","summary":"智通财经APP讯，回盛生物(300871.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润2.35亿元至2.71亿元，扭亏为盈;扣除非经常性损益后的净利润2.13亿元至2.49亿元。报告期内，公司积极开拓海内外市场，营业收入实现国内、国外双增长。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390886.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"回盛生物(300871.SZ)发预盈，预计2025年度归母净利润2.35亿元至2.71亿元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["300871"],"gpt_icon":0},{"id":"2601844958","title":"回盛生物：公司定增项目处于审核阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2601844958","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601844958?lang=zh_cn&edition=full","pubTime":"2026-01-07 08:42","pubTimestamp":1767746531,"startTime":"0","endTime":"0","summary":"证券之星消息，回盛生物(300871)01月06日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘您好，请问贵公司增发事项为何迟迟没有落地，目前进行到哪一步了？预计需要多久能够完成呢？回盛生物回复：尊敬的投资者，您好！公司定增项目处于审核阶段，相关进展情况公司将严格按照相关法律法规的规定履行信息披露义务。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700004996.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300871","BK0239"],"gpt_icon":0},{"id":"2593507448","title":"股市必读：回盛生物（300871）12月23日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2593507448","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593507448?lang=zh_cn&edition=full","pubTime":"2025-12-24 04:32","pubTimestamp":1766521933,"startTime":"0","endTime":"0","summary":"截至2025年12月23日收盘，回盛生物报收于20.73元，下跌0.81%，换手率1.72%，成交量3.48万手，成交额7216.14万元。关于使用部分闲置募集资金进行现金管理的公告武汉回盛生物科技股份有限公司于2025年12月23日召开第四届董事会第三次会议，审议通过使用部分闲置募集资金进行现金管理的议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400002968.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300871"],"gpt_icon":0},{"id":"2593504416","title":"回盛生物（300871）披露使用部分闲置募集资金进行现金管理，12月23日股价下跌0.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593504416","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593504416?lang=zh_cn&edition=full","pubTime":"2025-12-23 22:41","pubTimestamp":1766500885,"startTime":"0","endTime":"0","summary":"截至2025年12月23日收盘，回盛生物报收于20.73元，较前一交易日下跌0.81%，最新总市值为41.94亿元。该股当日开盘20.91元，最高21.05元，最低20.57元，成交额达7216.14万元，换手率为1.72%。公司近日发布公告称，于2025年12月23日召开第四届董事会第三次会议，审议通过《关于使用部分闲置募集资金进行现金管理的议案》。截至2025年11月30日，公司累计使用可转债募集资金66,090.19万元，募集资金余额为4,365.69万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300040977.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300871","BK0239"],"gpt_icon":0},{"id":"2593649851","title":"回盛生物：原料药产能利用率较高","url":"https://stock-news.laohu8.com/highlight/detail?id=2593649851","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593649851?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:24","pubTimestamp":1766478286,"startTime":"0","endTime":"0","summary":"证券之星消息，回盛生物(300871)12月23日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好:贵公司自从今年7月技改后，至现在12月中，目前泰乐菌素和泰万菌素原料药的总产能利用率是多少？是否达到满产满销状态？回盛生物回复：尊敬的投资者，您好！公司根据市场需求合理安排生产计划，原料药产能利用率较高，公司将在年度报告中披露原料药业务的经营情况。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300023009.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300871"],"gpt_icon":0},{"id":"2585452367","title":"回盛生物：二级市场股价受多种因素综合影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2585452367","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585452367?lang=zh_cn&edition=full","pubTime":"2025-11-24 16:36","pubTimestamp":1763973369,"startTime":"0","endTime":"0","summary":"证券之星消息，回盛生物(300871)11月24日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，您好。投资者情绪低迷是不是由低价增发引起的？为何贵公司收益不行的时候股价破净破发，收益好转了依旧破发下跌？全市场处于同一国情，为何贵公司市值还比不过同行业的ST绿康？回盛生物回复：尊敬的投资者您好！二级市场股价受宏观经济环境、市场波动、投资者情绪、公司经营情况等多种因素的综合影响。公司将聚焦主业，持续做好经营管理工作，提升公司竞争力与盈利能力。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400018028.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300871"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772749478292,"stockEarnings":[{"period":"1week","weight":-0.059},{"period":"1month","weight":-0.0989},{"period":"3month","weight":0.3057},{"period":"6month","weight":0.1409},{"period":"1year","weight":1.2588},{"period":"ytd","weight":0.2301}],"compareEarnings":[{"period":"1week","weight":-0.0092},{"period":"1month","weight":0.01},{"period":"3month","weight":0.0527},{"period":"6month","weight":0.0777},{"period":"1year","weight":0.2294},{"period":"ytd","weight":0.0352}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"武汉回盛生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"21150人(较上一季度减少10.03%)","perCapita":"9566股","listingDate":"2020-08-24","address":"湖北省武汉市东西湖区新沟街道办事处油纱路52号","registeredCapital":"20233万元","survey":" 武汉回盛生物科技股份有限公司的主营业务是兽用药品(包括化药制剂、原料药、中药制剂)、饲料及添加剂的研发、生产和销售。公司的主要产品是原料药、化药制剂、中药制剂、饲料及添加剂。","listedPrice":33.61},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"回盛生物(300871)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供回盛生物(300871)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"回盛生物,300871,回盛生物股票,回盛生物股票老虎,回盛生物股票老虎国际,回盛生物行情,回盛生物股票行情,回盛生物股价,回盛生物股市,回盛生物股票价格,回盛生物股票交易,回盛生物股票购买,回盛生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"回盛生物(300871)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供回盛生物(300871)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}